In vivo (Athens, Greece) · 2025
Optimal Sunitinib Dosing Based on Platelet Count in an Older Patient With Gastrointestinal Stromal Tumor.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suto Hirotaka, Kawamura Miyuki, Morita Mitsunori, Sakai Hideki, Onoe Takuma, Ikeuchi Kyoko, Matsumoto Koji
Аннотация
BACKGROUND/AIM: Sunitinib, a second-line treatment for gastrointestinal stromal tumors (GIST), is commonly associated with adverse events (AEs) such as myelosuppression in older patients. However, an optimal dosing schedule has not been established. This study evaluated the therapeutic efficacy and toxicity management of sunitinib administration based on platelet count.
CASE REPORT: An 83-year-old man receiving imatinib for rectal GISTs was switched to sunitinib (initially 50 mg/day) due to imatinib failure. After eight days, he developed grade 2 anorexia and nausea, prompting a dose reduction to 37.5 mg/day. These AEs persisted, and sunitinib was discontinued 15 days after treatment initiation and later resumed at 25 mg/day after the symptoms improved. Thereafter, the sunitinib withdrawal period was adjusted based on neutrophil and platelet counts. As a result, the only non-hematologic AE of grade 2 or higher was hypothyroidism, with no serious AEs. He achieved a partial response according to Choi criteria but was switched to regorafenib after five cycles of sunitinib due to disease progression. Changes in neutrophil and platelet counts during the withdrawal period of each cycle of sunitinib therapy were predicted using a quadratic regression model and validated using leave-one-out cross-validation. The coefficient of determination (R2) of the neutrophil count prediction model during the withdrawal period was 0.28, and the validated R2 for each cycle ranged from -26.34 to -0.11. In contrast, the platelet count model yielded an R2 value of 0.86, with validated R2 values ranging from 0.42 to 0.88.
CONCLUSION: Low-dose sunitinib monotherapy, with dosing intervals based on platelet counts, may be an effective treatment option for managing toxicity in older patients with imatinib-resistant GIST.
CASE REPORT: An 83-year-old man receiving imatinib for rectal GISTs was switched to sunitinib (initially 50 mg/day) due to imatinib failure. After eight days, he developed grade 2 anorexia and nausea, prompting a dose reduction to 37.5 mg/day. These AEs persisted, and sunitinib was discontinued 15 days after treatment initiation and later resumed at 25 mg/day after the symptoms improved. Thereafter, the sunitinib withdrawal period was adjusted based on neutrophil and platelet counts. As a result, the only non-hematologic AE of grade 2 or higher was hypothyroidism, with no serious AEs. He achieved a partial response according to Choi criteria but was switched to regorafenib after five cycles of sunitinib due to disease progression. Changes in neutrophil and platelet counts during the withdrawal period of each cycle of sunitinib therapy were predicted using a quadratic regression model and validated using leave-one-out cross-validation. The coefficient of determination (R2) of the neutrophil count prediction model during the withdrawal period was 0.28, and the validated R2 for each cycle ranged from -26.34 to -0.11. In contrast, the platelet count model yielded an R2 value of 0.86, with validated R2 values ranging from 0.42 to 0.88.
CONCLUSION: Low-dose sunitinib monotherapy, with dosing intervals based on platelet counts, may be an effective treatment option for managing toxicity in older patients with imatinib-resistant GIST.